新型療法在肌肉萎縮症治療上展現長期成效
New Treatment Shows Long-Term Success for Muscular Dystrophy
Updated at: June 27, 2026 at 03:15 AM
杜氏肌肉營養不良症(DMD)治療領域的最新突破，正將醫療前景從基礎的症狀管理轉向精準分子醫學。
Recent breakthroughs in treating Duchenne Muscular Dystrophy (DMD) are transforming the medical landscape from basic symptom management to precision molecular medicine.
DMD以缺乏抗肌萎縮蛋白為特徵，通常會導致肌肉退化和慢性發炎。
DMD, characterized by a lack of dystrophin, typically results in muscle degeneration and chronic inflammation.
傳統上，照護極度依賴皮質類固醇。
Traditionally, care relied heavily on corticosteroids.
除了藥物療法，研究人員正在開創克服傳統限制的基因傳遞平台。
Beyond drug therapy, researchers are pioneering gene delivery platforms that overcome traditional limitations.
截至2026年6月，一項值得注意的創新涉及利用細胞外囊泡來傳遞全長DMD基因。
A notable innovation as of June 2026 involves using extracellular vesicles to deliver the full-length DMD gene.
與可能引發免疫反應的病毒基底方法不同，這些工程化粒子能在臨床前模型中安全且有效地恢復抗肌萎縮蛋白的產生。
Unlike viral-based methods, which can trigger immune reactions, these engineered particles restore dystrophin production safely and effectively in preclinical models.
具體而言，研究人員正致力於解決「心臟缺口」問題，以預防導致DMD患者死亡的首要原因——心臟衰竭。
Specifically, researchers are tackling the 'heart gap' to prevent cardiac failure, the leading cause of mortality in DMD.
隨著這些策略的演進，目標十分明確：透過創新且具標靶性的科學，延長生命、增強肌肉耐力並提供持久的功能穩定性。
As these strategies evolve, the goal is clear: to extend lives, enhance muscle endurance, and provide lasting functional stability through innovative, targeted science.
